<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1682-0037</journal-id>
<journal-title><![CDATA[Revista Cubana de Angiología y Cirugía Vascular]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Angiol Cir Vasc]]></abbrev-journal-title>
<issn>1682-0037</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1682-00372020000300012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Lesiones complejas en pie diabético neuroinfeccioso y su tratamiento con Heberprot-P®]]></article-title>
<article-title xml:lang="en"><![CDATA[Complex lesions in neuroinfectious diabetic foot and its treatment with Heberprot-P®]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ascaño Ortega]]></surname>
<given-names><![CDATA[Alicia Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Militar &#8220;Dr. Mario Muñoz Monroy&#8221;  ]]></institution>
<addr-line><![CDATA[Matanzas ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1682-00372020000300012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1682-00372020000300012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1682-00372020000300012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La prevalencia mundial del pie diabético oscila en un 6,4 %. La amputación en personas con diabetes es de 10 a 20 veces más frecuente que en los no diabéticos y, cada 30 segundos, en algún lugar del mundo alguien sufre la amputación de una extremidad inferior como consecuencia de esta. El Heberprot-P® constituye un producto indicado y registrado por Cuba para el tratamiento de pacientes con úlceras neuropáticas y neuroisquémicas del pie diabético, que en este caso resulta una lesión compleja, en estado avanzado y con alto riesgo de amputación (Wagner 4). Este estudio tuvo como objetivo presentar un caso que demuestra la eficacia de la cicatrización de una lesión compleja del pie diabético mediante el tratamiento con Heberprot-P®. Se trata de un paciente de 47 años, diabético de tipo 1, que ingresó en el Hospital &#8220;Dr. Mario Muñoz Monroy&#8221; de la provincia de Matanzas, en 2017, con el diagnóstico de pie diabético neuroinfeccioso, y lesiones en primer dedo y base plantar de todos los dedos (grado 4, según clasificación de Wagner). Se le realizó desarticulación del primer dedo y necrectomía plantar. Posteriormente, previo control metabólico y de la sepsis, se le hicieron 21 infiltraciones de Heberprot-P® (75 µg) en un período de 45 días. Finalmente, se logró una epitelización de aproximadamente un 95 % de la lesión. De este modo, quedó mostrada la eficacia en la cicatrización de lesiones complejas del pie diabético mediante el uso del Heberprot-P®.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The global prevalence of diabetic foot ranges from 6.4%. Amputation in people with diabetes is 10 to 20 times more common than in non-diabetics and every 30 seconds somewhere in the world someone suffers the amputation of a lower limb as a result of diabetes. Heberprot-P® constitutes a product indicated and registered by Cuba for the treatment of patients with neuropathic and neuroischemic ulcers of the diabetic foot, which in this case results in a complex injury, in advanced state and with high risk of amputation (Wagner 4). This study aimed to present a case that demonstrates the effectiveness of healing from a complex diabetic foot wound treated with Heberprot-P®. It was the case of a 47-year-old male diabetic type 1 patient who was admitted at "Dr. Mario Muñoz Monroy" Hospital in Matanzas province, in 2017, with the diagnosis of neuroinfectious diabetic foot, and lesions in the first finger and plantar base of all fingers (grade 4, according to Wagner's classification). It was conducted a disarticulation of the first toe and a plantar necrectomy. Subsequently, after metabolic control and sepsis, 21 infiltrations of Heberprot-P® (75 g) were made over a period of 45 days. Finally, an epithelialization of approximately 95% of the wound was achieved. In this way, the effectiveness in healing complex lesions of the diabetic foot was shown through the use of Heberprot-P®.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[pie diabético]]></kwd>
<kwd lng="es"><![CDATA[cicatrización]]></kwd>
<kwd lng="es"><![CDATA[Heberprot-P®]]></kwd>
<kwd lng="en"><![CDATA[Diabetic foot]]></kwd>
<kwd lng="en"><![CDATA[healing]]></kwd>
<kwd lng="en"><![CDATA[Heberprot-P®]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Federación Internacional de Diabetes (FID)</collab>
<source><![CDATA[Diabetes Atlas de la FID]]></source>
<year>2017</year>
<edition>8</edition>
<publisher-name><![CDATA[FID]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional</collab>
<source><![CDATA[Diabetes. Estadísticas Mundiales. Facto gráfico salud]]></source>
<year>2019</year>
<volume>5</volume>
<publisher-loc><![CDATA[Cuba ]]></publisher-loc>
<publisher-name><![CDATA[CNICM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Diabetes]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>American Diabetes Association (ADA)</collab>
<source><![CDATA[Datos sobre la diabetes]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Washington D.C. ]]></publisher-loc>
<publisher-name><![CDATA[ADA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damas-Casani]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Yovera-Aldana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Seclén Santisteban]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación de pie en riesgo de ulceración según el Sistema IWGDF y factores asociados en pacientes con diabetes mellitus tipo 2 de un hospital peruano]]></article-title>
<source><![CDATA[Rev Med Hered]]></source>
<year>2017</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-12</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Boulton]]></surname>
<given-names><![CDATA[AJM]]></given-names>
</name>
<name>
<surname><![CDATA[Bus]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic Foot Ulcers and Their Recurrence]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2367-75</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mesa Pérez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Peregrino Callis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rosell Valdenebro]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fong Sorribe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costo-beneficio del tratamiento con Heberprot-P(r) en pacientes con pie diabético]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2018</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-33</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Cañete]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Jácome Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Iturralde Mc Farlen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Montiel]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados y reacciones adversas en pacientes tratados con Heberprot-P(r) en la comunidad]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Gálvez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Rodríguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Úlcera del pie diabético tratado con Heberprot-p(r)]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2020</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdaguer Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada Ladoy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrán Bahades]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicación del Heberprot-P(r) en un paciente con pie diabético neuroinfeccioso]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2029-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Herrera]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnóstico y tratamiento del pie diabético]]></source>
<year>2017</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>World Medical Association (WMA)</collab>
<article-title xml:lang=""><![CDATA[Declaration of Helsinki. Ethical principles for medical research involving human subjects. 64th WMA general assembly. Fortaleza, Brazil, October 2013. Updated Helsinki guidelines for clinical research get mixed reviews]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabelo Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Leonard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución de las úlceras de pie diabético con el tratamiento mixto de Heberprot-P(r) y ozonoterapia]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2019</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Montequín]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera Martínez]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Negrín Martínez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berlanga Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López Mola]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Pavón]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual de promotores Heberprot P. Una herramienta imprescindible para los heberpropistas]]></source>
<year>2011</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Elfos Scientiae]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wieman]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smiell]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>1998</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>822-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
<name>
<surname><![CDATA[Garner]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Biundo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Giancalone]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) gel 0,01 % is an effective adjunct to the treatment of diabetic foot ulcers]]></article-title>
<source><![CDATA[J Appl Res]]></source>
<year>2005</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-45</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Saura]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Year Alos]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela Silva]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[González Díaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Río Martín]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Berlanga Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical practice confirms clinical trial results of the use of intralesional human recombinant epidermal growth factor in advanced diabetic foot ulcers. Advances in Pharmacoepidemiology &amp; Drug Safety]]></article-title>
<source><![CDATA[BMC Pharmacol Toxicol]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yera-Alos]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso-Carbonell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Valenzuela-Silva]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Tuero-Iglesias]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marrero-Rodríguez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[López-Mola]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[López-Saura]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers]]></article-title>
<source><![CDATA[BMC Pharmacol Toxicol]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dumville]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Meara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deshpande]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Speak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hydrogel dressings for healing diabetic foot ulcers]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>2013</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dumville]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[O&amp;apos;Meara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deshpande]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Speak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alginate dressings for healing diabetic foot ulcers]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2013</year>
<volume>2013</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Margara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boriani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Obbialero]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Bocchiotti]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency Rhythmic Electrical Modulation System in the treatment of diabetic ulcers. Preliminary encouraging report]]></article-title>
<source><![CDATA[Chirurgia]]></source>
<year>2008</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>311-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero Gamboa]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Sández López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del pie diabético en los grados 4 y 5 de la clasificación de Wagner]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2017</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-81</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez Duarte]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Carretero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arpajón Peña]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gálvez Valcárcel]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Reynaldo Concepción]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jay Carbonell]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beneficios de la intervención con ozonoterapia en pacientes con pie diabético neuroinfeccioso]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2014</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-21</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="book">
<collab>Centre for Clinical Practice at NICE (UK)</collab>
<source><![CDATA[Diabetic Foot Problems: Inpatient Management of Diabetic Foot Problems]]></source>
<year>2011</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[National Institute for Health and Clinical Excellence (UK)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andros]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Attinger]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Boulton]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Frykberg]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Lavery]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Morbach]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Niezgoda]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Toursarkissian]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<collab>Tucson Expert Consensus Conference</collab>
<article-title xml:lang=""><![CDATA[Consensus statement on negative pressure wound therapy (V.A.C. Therapy) for the management of diabetic foot wounds]]></article-title>
<source><![CDATA[Ostomy Wound Manage]]></source>
<year>2006</year>
<numero>^s1-32</numero>
<issue>^s1-32</issue>
<supplement>1-32</supplement>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
